MA71661A - Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées - Google Patents

Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées

Info

Publication number
MA71661A
MA71661A MA71661A MA71661A MA71661A MA 71661 A MA71661 A MA 71661A MA 71661 A MA71661 A MA 71661A MA 71661 A MA71661 A MA 71661A MA 71661 A MA71661 A MA 71661A
Authority
MA
Morocco
Prior art keywords
enzymes
fusion proteins
related methods
sulfoglucosamine sulfohydrolase
sulfohydrolase
Prior art date
Application number
MA71661A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Mihalis Kariolis
Cathal Mahon
Tina GIESE
Original Assignee
Denali Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc. filed Critical Denali Therapeutics Inc.
Publication of MA71661A publication Critical patent/MA71661A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y310/00Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y310/00Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA71661A 2020-10-14 2021-10-13 Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées MA71661A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091800P 2020-10-14 2020-10-14
PCT/US2021/054860 WO2022081765A1 (fr) 2020-10-14 2021-10-13 Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées
EP21811560.8A EP4229192A1 (fr) 2020-10-14 2021-10-13 Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées

Publications (1)

Publication Number Publication Date
MA71661A true MA71661A (fr) 2025-05-30

Family

ID=78725609

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71661A MA71661A (fr) 2020-10-14 2021-10-13 Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées

Country Status (18)

Country Link
US (2) US11884944B2 (fr)
EP (1) EP4229192A1 (fr)
JP (1) JP2023545707A (fr)
KR (1) KR20230086703A (fr)
CN (1) CN116916947A (fr)
AR (1) AR123788A1 (fr)
AU (1) AU2021362209B2 (fr)
CA (1) CA3197506A1 (fr)
CL (1) CL2023001034A1 (fr)
CO (1) CO2023005260A2 (fr)
CR (1) CR20230178A (fr)
EC (1) ECSP23035251A (fr)
IL (1) IL302029A (fr)
MA (1) MA71661A (fr)
MX (1) MX2023004335A (fr)
PE (1) PE20231931A1 (fr)
TW (1) TW202229547A (fr)
WO (1) WO2022081765A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2932759T3 (es) 2017-02-17 2023-01-25 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina diseñados
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
CN113614110B (zh) 2019-02-20 2025-03-25 戴纳立制药公司 抗trem2抗体及其使用方法
AU2020411480B2 (en) 2019-12-23 2023-12-21 Denali Therapeutics Inc. Progranulin variants
WO2025137213A1 (fr) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Protéines de fusion comprenant des enzymes alpha-glucosidase acides et méthodes associées

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2006506317A (ja) 2002-01-11 2006-02-23 バイオマリン ファーマシューティカル インコーポレイテッド 治療用リソソーム酵素の送達のための酵素送達系としてのp97の使用
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
MX2010007846A (es) 2008-01-18 2010-10-05 Biomarin Pharm Inc Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas.
EP2394667A1 (fr) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vecteurs et séquences pour le traitement de maladies
RU2012154576A (ru) 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
CN104857504A (zh) 2010-06-25 2015-08-26 夏尔人类遗传性治疗公司 芳基硫酸酯酶a cns递送的方法和组合物
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
EP2739649B1 (fr) 2011-08-05 2017-09-27 Bioasis Technologies Inc. Fragments de p97 avec activité de transfert
CN104662150B (zh) 2012-07-31 2018-07-10 比奥阿赛斯技术有限公司 脱磷酸化的溶酶体贮积症蛋白及其使用方法
KR20190121874A (ko) 2012-08-29 2019-10-28 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
JP6586412B2 (ja) 2013-03-13 2019-10-02 バイオアシス テクノロジーズ インコーポレイテッド p97のフラグメントおよびその使用
US20160184458A1 (en) 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
JP6692293B2 (ja) 2013-07-22 2020-05-13 アーマジェン・インコーポレイテッドArmagen, Inc. Cnsにおける酵素活性を増大するための方法および組成物
PT2970413T (pt) 2014-04-01 2018-10-23 Swedish Orphan Biovitrum Ab Publ Sulfamidase modificada e sua produção
SI3215528T1 (sl) 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法
PE20221007A1 (es) 2015-06-24 2022-06-15 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
TWI769982B (zh) 2015-06-24 2022-07-11 日商Jcr製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
IL287019B2 (en) 2015-12-08 2025-10-01 Regeneron Pharma Preparations and methods for internalizing enzymes
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
EP4275751A3 (fr) 2016-02-24 2023-12-27 BioMarin Pharmaceutical Inc. Formulation de la protéine de fusion naglu améliorée
WO2018031424A1 (fr) 2016-08-06 2018-02-15 Ossianix, Inc. Méthodes in vivo pour sélectionner des peptides qui traversent la barrière hémato-encéphalique, compositions apparentées et procédés d'utilisation
CA3034589A1 (fr) 2016-08-25 2018-03-01 Jcr Pharmaceuticals Co., Ltd. Procede de production d'une proteine de fusion d'anticorps
WO2018117613A1 (fr) 2016-12-19 2018-06-28 한미약품 주식회사 Conjugué de protéine à action prolongée ciblant le cerveau
CN109983031B (zh) * 2016-12-26 2022-11-25 Jcr制药股份有限公司 通过血脑屏障的新的抗人转铁蛋白受体抗体
JP7042220B2 (ja) 2016-12-28 2022-03-25 Jcrファーマ株式会社 凍結乾燥製剤
JP2020508054A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 抗タウ抗体及びその使用方法
ES2932759T3 (es) 2017-02-17 2023-01-25 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina diseñados
EP3583118B1 (fr) 2017-02-17 2025-06-11 Denali Therapeutics Inc. Modèles transgéniques de récepteur de transferrine
GB201702863D0 (en) 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
IL271837B2 (en) 2017-07-07 2024-01-01 Hanmi Pharm Ind Co Ltd Novel therapeutic enzyme fusion protein and use thereof
EP3665194A4 (fr) 2017-08-10 2021-07-07 Denali Therapeutics Inc. Procédés basés sur l'affinité pour utiliser des protéines de liaison au récepteur de transferrine
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
WO2019094608A1 (fr) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps anti-bace1 et leurs procédés d'utilisation
BR112020012346A2 (pt) 2017-12-22 2020-11-24 Hanmi Pharm. Co., Ltd. proteína de fusão enzimática terapêutica tendo uma nova estrutura e uso da mesma
WO2019140050A1 (fr) 2018-01-10 2019-07-18 Denali Therapeutics Inc. Polypeptides de liaison au récepteur de la transferrine et utilisations associées
WO2019145500A1 (fr) 2018-01-26 2019-08-01 Swedish Orphan Biovitrum Ab (Publ) Méthode de traitement
TW202448946A (zh) * 2018-05-25 2024-12-16 美商阿列克特有限責任公司 抗-sirpa 抗體及其使用方法
US20210284702A1 (en) 2018-06-18 2021-09-16 Denali Therapeutics Inc. Fusion proteins comprising progranulin
CN112839955A (zh) 2018-08-16 2021-05-25 戴纳立制药公司 经工程改造双特异性蛋白
TW202017947A (zh) 2018-08-22 2020-05-16 美商戴納立製藥公司 抗her2 多肽及其使用方法
SG11202101552SA (en) * 2018-08-31 2021-03-30 Alector Llc Anti-cd33 antibodies and methods of use thereof
KR20220004651A (ko) 2019-04-03 2022-01-11 데날리 테라퓨틱스 인크. 이두로네이트 2-설파타제를 포함하는 단백질 분자의 제제
WO2021133907A1 (fr) 2019-12-23 2021-07-01 Denali Therapeutics Inc. Variants de la progranuline
AU2020411480B2 (en) 2019-12-23 2023-12-21 Denali Therapeutics Inc. Progranulin variants
WO2021146256A1 (fr) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anticorps anti-trem2 et leurs procédés d'utilisation
AU2021208482B2 (en) 2020-01-13 2025-12-11 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
EP4100419A4 (fr) 2020-02-07 2024-05-29 Denali Therapeutics Inc. Procédés de traitement de la maladie de hunter
BR112022016232A2 (pt) 2020-02-19 2022-11-16 Denali Therapeutics Inc Proteínas biespecíficas anti-her2 manipuladas

Also Published As

Publication number Publication date
AU2021362209A1 (en) 2023-05-18
PE20231931A1 (es) 2023-12-01
CA3197506A1 (fr) 2022-04-21
IL302029A (en) 2023-06-01
TW202229547A (zh) 2022-08-01
AU2021362209B2 (en) 2026-02-12
US20240150736A1 (en) 2024-05-09
US11884944B2 (en) 2024-01-30
ECSP23035251A (es) 2023-10-31
CL2023001034A1 (es) 2023-10-06
JP2023545707A (ja) 2023-10-31
US20230062800A1 (en) 2023-03-02
CN116916947A (zh) 2023-10-20
CO2023005260A2 (es) 2023-05-19
KR20230086703A (ko) 2023-06-15
EP4229192A1 (fr) 2023-08-23
AR123788A1 (es) 2023-01-11
CR20230178A (es) 2023-07-26
WO2022081765A1 (fr) 2022-04-21
MX2023004335A (es) 2023-05-04

Similar Documents

Publication Publication Date Title
MA71661A (fr) Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées
EP2023941A4 (fr) Agents de réticulation de protéine, méthodes de réticulation et leurs applications
MA50746A (fr) Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
EP3918062A4 (fr) Variants de subtilase et compositions les comprenant
BRPI0918027A2 (pt) enzimas de lise de peptidoglicano artificial e proteínas de ligação de peptidoglicano
EP1877090A4 (fr) Proteine de fusion trimere immunoglobulinique ox-40 et procedes d'utilisation
EP4211234A4 (fr) Enzymes d'édition de base
EP2007884A4 (fr) Proteines de fusion enzymatiques et leur utilisation
MX377150B (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas.
DK1844074T3 (da) Humane antistoffer og proteiner
MX2012007684A (es) Modificacion covalente ligando dirigida de proteina.
MA50354A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation
NL2000626A1 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
EP4203998A4 (fr) Protéines de fusion de coronavirus immunogènes et méthodes associées
EP3715377A4 (fr) Protéine de fusion bifonctionnelle ciblant cd47 et pd-l1
DK1913136T3 (da) Fusionsproteiner mellem plantecellevæg-nedbrydende enzymer og anvendelser deraf
EP3976630A4 (fr) Protéines de liaison à actrii et leurs utilisations
EP3331543A4 (fr) Conjugués de pénétration cellulaire formés de protéine et d'anticorps et méthodes d'utilisation
EP4426826A4 (fr) Enzymes d'édition de base
EP4065702A4 (fr) Système et méthodes d'activation d'expression génique
EP4171603A4 (fr) Protéines de fusion ace2-fc et méthodes d'utilisation
EP4190803A4 (fr) PROTÉINE DE FUSION SIRPa-FC
WO2008054595A3 (fr) Étiquettes moléculaires contrôlées par médicament
EP4370594A4 (fr) Enzymes et leurs utilisations
EP3943601A4 (fr) Traduction de protéines à l'aide d'arn circulaire et son application